Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) — VMCI valuation read

Headline read on 300436.SZ: VMCI of 34/100 versus a Healthcare sector median of 50. The 16-point below-median position is what makes Fujian Cosunter Pharmaceutical Co., Ltd. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 300436.SZ: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 300436.SZ: value (300436.SZ trades at 21.0x earnings, 17% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -0.7x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

300436.SZ rose 1.4% over the trailing 7 days, with a +1.4% read on a 30-day basis.